Renomer is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.

Renomer is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus > 1.78 mmol/l.

Renomer should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.

Posology

Starting dose

The recommended starting dose of sevelamer carbonate is 2.4 g or 4.8 g per day based on clinical needs and serum phosphorus level. Renomer must be taken three times per day with meals.

For patients previously on phosphate binders (sevelamer hydrochloride or calcium based), Renomer should be given on a gram for gram basis with monitoring of serum phosphorus levels to ensure optimal daily doses.

Titration and Maintenance

Serum phosphorus levels must be monitored and the dose of sevelamer carbonate titrated by increasing the dose of 0.8 g three times a day (2.4 g / day)every 2-4 weeks until an acceptable serum phosphorus level is reached, with regular monitoring thereafter.

Patients taking Renomer should adhere to their prescribed diets.

In clinical practice, treatment will be continuous based on the need to control serum phosphorus levels and the daily dose is expected to be an average of approximately 6 g per day.

Paediatric population

The safety and efficacy of has not been established in children below the age of 18 years.

Method of administration

For oral use.

Tablets should be swallowed intact and should not be crushed, chewed, or broken into pieces prior to administration.

The safety and efficacy of sevelamer carbonate have not been established in adult patients with chronic kidney disease not on dialysis with serum phosphorus < 1.78 mmol/l. Therefore Renomeris currently not recommended for use in these patients.

The safety and efficacy of sevelamer carbonate have not been established in patients with the following disorders:

·       Dysphagia

·       swallowing disorders

·       severe gastrointestinal motility disorders including untreated or severe gastroparesis, retention ofgastric contents and abnormal or irregular bowel motion

·       active inflammatory bowel disease

·       major gastrointestinal tract surgery

Therefore caution should be exercised when Renomer is used in these patients.

Intestinal obstruction and ileus/subileus

In very rare cases, intestinal obstruction and ileus/subileus have been observed in patients during treatment with sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate. Constipation may be a preceding symptom. Patients who are constipated should be monitored carefully while being treated with Renomer. Renomertreatment should be re-evaluated in patients who develop severe constipation or other severe gastrointestinal symptoms.

Fat-soluble vitamins

Patients with CKD may develop low levels of fat-soluble vitamins A, D, E and K, depending on dietaryintake and the severity of their disease. It cannot be excluded that Renomer can bind fat-soluble vitaminscontained in ingested food. In patients not taking supplemental vitamins but on sevelamer, serum vitamin A,D, E and K status should be assessed regularly. It is recommended that vitamin supplements be given ifnecessary. It is recommended that CKD patients not on dialysis are given vitamin D supplements(approximately 400 IU of native vitamin D daily) which can be part of a multivitamin preparation to be takenapart from their dose of Renomer. In patients undergoing peritoneal dialysis additional monitoring of fatsolublevitamins and folic acid is recommended, since vitamin A, D, E and K levels were not measured in aclinical study in these patients.

Folate deficiency

There is at present insufficient data to exclude the possibility of folate deficiency during long term sevelamer carbonate treatment.

Hypocalcaemia/hypercalcaemia

Patients with renal insufficiencymay develop hypocalcaemia or hypercalcaemia. Renomerdoes not contain any calcium.

Serum calcium levels should be monitored as is done in normal follow-up of a dialysis patient.Elemental calcium should be given as a supplement in case of hypocalcaemia.

Metabolic acidosis

Patients with chronic kidney disease are predisposed to developing metabolic acidosis. As part of goodclinical practice, monitoring of serum bicarbonate levels is therefore recommended.

Peritonitis

Patients receiving dialysis are subject to certain risks for infection specific to dialysis modality. Peritonitis isa known complication in patients receiving peritoneal dialysis and in a clinical study with sevelamerhydrochloride, a greater number of peritonitis cases were reported in the sevelamer group than in the controlgroup. Patients on peritoneal dialysis should be closely monitored to ensure the correct use of appropriateaseptic technique with the prompt recognition and management of any signs and symptoms associated withperitonitis.

Swallowing and choking difficulties

Uncommon reports of difficulty swallowing the sevelamer carbonate tablet have been reported. Many of these cases involved patients with co-morbid conditions including swallowing disorders or oesophageal abnormalities. Caution should be exercised when Renomer is used in patients with difficulty swallowing.

Hypothyroidism

Closer monitoring of patients with hypothyroidism co-administered with sevelamer carbonate and levothryroxine is recommended (see section 4.5).

Long-term chronic treatment

In a clinical trial of one year, no evidence of accumulation of sevelamer was seen. However the potentialabsorption and accumulation of sevelamer during long-term chronic treatment (> one year) cannot be totallyexcluded (see section 5.2).

Hyperparathyroidism

Renomer is not indicated for the control of hyperparathyroidism. In patients with secondaryhyperparathyroidism Renomershould be used within the context of a multiple therapeutic approach, whichcould include calcium as supplements, 1,25 - dihydroxy Vitamin D3 or one of its analogues to lower theintact parathyroid hormone (iPTH) levels.

Dialysis

Interaction studies have not been conducted in patients on dialysis.

Ciprofloxacin

In interaction studies in healthy volunteers, sevelamer hydrochloride, which contains the same active moiety as Renomer, decreased the bioavailability of ciprofloxacin by approximately 50% when co-administered with sevelamer hydrochloride in a single dose study. Consequently, Renomershould not be taken simultaneously with ciprofloxacin.

Ciclosporin, mycophenolatemofetil and tacrolimus in transplant patients

Reduced levels of ciclosporin, mycophenolatemofetil and tacrolimus have been reported in transplant patients when co-administered with sevelamer hydrochloride without any clinical consequences (i.e graft rejection). The possibility of an interaction cannot be excluded and a close monitoring of blood concentrations of ciclosporin, mycophenolatemofetil and tacrolimus should be considered during the use of combination and after its withdrawal.

Levothyroxine

Very rare cases of hypothyroidism have been reported in patients co-administered sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, and levothyroxine. Closer monitoring of thyroid stimulating hormone (TSH) levels is therefore recommended in patients receiving sevelamercarbonate and levothyroxine.

Anti-arrhythmics and anti-seizure medicinal products

Patients taking anti-arrhythmic medicinal products for the control of arrhythmias and anti-seizure medicinal products for the control of seizure disorders were excluded from clinical trials. Caution should be exercised when prescribing Renomer to patients also taking these medicinal products.

Digoxin, warfarin, enalapril or metoprolol

In interaction studies in healthy volunteers, sevelamer hydrochloride, which contains the same active moiety as Renomer,had no effect on the bioavailability of digoxin, warfarin, enalapril or metoprolol.

Bioavailability

Renomeris not absorbed and may affect the bioavailability of other medicinal products. When administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after Renomer, or the physician should consider monitoring blood levels.

Pregnancy

There are no data from the use of sevelamer in pregnant women. Studies in animals have shown somereproductive toxicity when sevelamer was administered to rats at high doses (see section 5.3).

Sevelamer hasalso been shown to reduce the absorption of several vitamins including folic acid (see sections 4.4 and 5.3).The potential risk to humans is unknown. Renomershould only be given to pregnant women if clearly neededand after a careful risk/benefit analysis has been conducted for both the mother and the foetus.

Breast-feeding

It is unknown whether sevelamer is excreted in human breast milk. The non-absorbed nature of sevelamerindicates that excretion of sevelamer in breast milk is unlikely. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Renomershould be made taking into account the benefit of breast-feeding to the child and the benefit of Renomertherapy to the woman.

Fertility

There are no data from the effect of sevelamer on fertility in humans. Studies in animals have shown that sevelamer did not impair fertility in male or female rats at exposures at a human equivalent dose 2 times the maximum clinical trial dose of 13 g/day, based on a comparison of relative body surface area.

No studies on the effects on ability to drive and use machines have been performed.

Summary of the safety profile

The most frequently occurring (≥ 5% of patients) undesirable effects possibly or probably related to sevelamer were all in the gastrointestinal disorders system organ class. Most of these adverse reactions were mild to moderate in intensity.

Tabulated list of adverse reactions

The safety of sevelamer (as either carbonate and hydrochloride salts) has been investigated in numerous clinical trials involving a total of 969 haemodialysis patients with treatment duration of 4 to 50 weeks (724 patients treated with sevelamer hydrochloride and 245 with sevelamer carbonate), 97 peritoneal dialysis patients with treatment duration of 12 weeks (all treated with sevelamer hydrochloride) and 128 patients with CKD not on dialysis with treatment duration of 8 to 12 weeks (79 patients treatment with sevelamerhydrochloride and 49 with sevelamer carbonate).

Adverse reactions are listed by frequency in the table below. The incidence of the following categories: very common (≥ 1/10), common (≥ 1/100, <1/10), uncommon (≥ 1/1 000, <1/100), rare (≥ 1/10 000, <1/1, 000), very rare (<1/10 000), not known (because the available data cannot be estimated).

No cases of overdose have been reported. Sevelamer hydrochloride, which contains the same active moietyas sevelamer carbonate, has been given to normal healthy volunteers in doses of up to 14 grams per day foreight days with no undesirable effects. In CKD patients, the maximum average daily dose studied was14.4 grams of sevelamer carbonate in a single daily dose.

Pharmacotherapeutic group: Treatment of hyperphosphataemia. ATC code: V03A E02.

Renomercontains sevelamer, a non-absorbed phosphate binding crosslinked polymer, free of metal and calcium. Sevelamer contains multiple amines separated by one carbon from the polymer backbone which become protonated in the stomach. These protonated amines bind negatively charged ions such as dietary phosphate in the intestine. By binding phosphate in the gastrointestinal tract and decreasing absorption, sevelamer lowers the phosphorus concentration in the serum. Regular monitoring of serum phosphorus levels is always necessary during phosphate binder administration.

In two randomised, cross over clinical studies, sevelamer carbonate in both tablet and powder formulationswhen administered three times per day has been shown to be therapeutically equivalent to sevelamerhydrochloride and therefore effective in controlling serum phosphorus in CKD patients on haemodialysis.

The first study demonstrated that sevelamer carbonate tablets dosed three times per day was equivalent tosevelamer hydrochloride tablets dosed three times per day in 79 haemodialysis patients treated over tworandomised 8 week treatment periods (mean serum phosphorus time-weighted averages were1.5 ± 0.3 mmol/l for both sevelamer carbonate and sevelamer hydrochloride). The second studydemonstrated that sevelamer carbonate powder dosed three times per day was equivalent to sevelamerhydrochloride tablets dosed three times per day in 31 hyperphosphataemic (defined as serum phosphoruslevels ≥ 1.78 mmol/l) haemodialysis patients over two randomised 4 week treatment periods (mean serumphosphorus time-weighted averages were 1.6 ± 0.5 mmol/l for sevelamer carbonate powder and 1.7 ±

0.4 mmol/l for sevelamer hydrochloride tablets).

In the clinical studies in haemodialysis patients, sevelamer alone did not have a consistent and clinically significant effect on serum intact parathyroid hormone (iPTH). In a 12 week study involving peritoneal dialysis patients however, similar iPTH reductions were seen compared with patients receiving calcium acetate. In patients with secondary hyperparathyroidism sevelamer carbonate should be used within the context of a multiple therapeutic approach, which could include calcium as supplements, 1,25 – dihydroxy Vitamin D3 or one of its analogues to lower the intact parathyroid hormone (iPTH) levels.

Sevelamer has been shown to bind bile acids in vitro and in vivo in experimental animal models. Bile acidbinding by ion exchange resins is a well-established method of lowering blood cholesterol. In clinical trialsof sevelamer, both the mean total-cholesterol and LDL-cholesterol declined by 15-39%. The decrease incholesterol has been observed after 2 weeks of treatment and is maintained with long-term treatment.

Triglycerides, HDL-cholesterol and albumin levels did not change following sevelamer treatment.

Because sevelamer binds bile acids, it may interfere with the absorption of fat soluble vitamins such as A, D,E and K.

Sevelamer does not contain calcium and decreases the incidence of hypercalcaemic episodes as compared topatients using calcium based phosphate binders alone. The effects of sevelamer on phosphorus and calciumwere proven to be maintained throughout a study with one year follow-up. This information was obtainedfrom studies in which sevelamer hydrochloride was used.

Pharmacokinetic studies have not been carried out with sevelamer carbonate. Sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, is not absorbed from the gastrointestinal tract, as confirmed by an absorption study in healthy volunteers.

Non-clinical data with sevelamer reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity or genotoxicity.

Carcinogenicity studies with oral sevelamer hydrochloride were conducted in mice (doses of up to 9 g/kg/day) and rats (0.3, 1, or 3 g/kg/day). There was an increased incidence of urinary bladder transitional cell papilloma in male rats of the high dose group (human equivalent dose twice the maximum clinical trial dose of 14.4 g). There was no increased incidence of tumors observed in mice (human equivalent dose 3 times the maximum clinical trial dose).

In an in vitro mammalian cytogenetic test with metabolic activation, sevelamer hydrochloride caused a statistically significant increase in the number of structural chromosome aberrations. Sevelamerhydrochloride was not mutagenic in the Ames bacterial mutation assay.

In rats and dogs, sevelamer reduced absorption of fat soluble vitamins D, E and K (coagulation factors), and folic acid.

Deficits in skeletal ossification were observed in several locations in foetuses of female rats dosed with sevelamer at intermediate and high doses (human equivalent dose less than the maximum clinical trial dose of 14.4 g). The effects may be secondary to vitamin D depletion.

In pregnant rabbits given oral doses of sevelamer hydrochloride by gavage during organogenesis, an increase of early resorptions occurred in the high-dose group (human equivalent dose twice the maximum clinical trial dose).

Sevelamer hydrochloride did not impair the fertility of male or female rats in a dietary administration study in which the females were treated from 14 days prior to mating through gestation and the males were treated for 28 days prior to mating. The highest dose in this study was 4.5 g/kg/day (human equivalent dose 2 times the maximum clinical trial dose of 13 g/day, based on a comparison of relative body surface area).

Tablet core:

Silica, Colloidal Anhydrous: 100.00 mg.

Pregelatinized Starch: 52.00 mg.

Magnesium Stearate: 48.00 mg.

Tablet coating

Hypromellose 15Cp (E464)

HPMC 2910/Hypromellose 5Cp (E464)

Acetylated Monoglycerides FCC (E472a)

Not applicable.

Store below 30°C.

Keep the bottle tightly closed in order to protect from moisture.

This medicinal product does not require any special temperature storage conditions.

 A cardboard box containing a white opaque HDPE bottlecontaining 30 or 180 tablets with PP child resistant cap and a foil induction seal.

A white opaque HDPE bottle, containing 30 or 180 tablets with PP child resistant cap and a foil induction seal.

Not all pack sizes may be marketed.

No special requirements for disposal.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.